Compare Fidelity National Information Servcs Inc (FIS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Inovio Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Fidelity National Information Servcs Inc is far larger — about 157.9× Inovio Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FIS | INO | |
|---|---|---|
Market Cap | $17.71B | $112.19M |
Volume | 9,047,825 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $67.94 | $2.60 |
52-Week Low | $32.44 | $0.66 |
Typical Hold Time | 88 Days | 43 Days |
Enterprise Value | $38.22B | $83.51M |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while profitability has improved significantly with net income margin reaching 27.65% in 2026 projections. Recent business developments include multiple core banking platform wins and new product launches, positioning the company for growth in financial technology modernization.
FIS presents a compelling value opportunity with strong analyst support (56.76% buy ratings) and a $47.15 consensus price target representing 37% upside. However, investors face risks from the company's elevated debt levels and inconsistent cash flow generation. The technical bearish signal and recent price weakness suggest potential near-term volatility despite fundamental improvements.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
